StockData
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. (ACRS) stock

ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.38−0.23 (-6.24%)

Close on Nov 17, 2026Market cap $497.53MP/E –Yield –

Aclaris Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Aclaris Therapeutics's price to sales ratio was 73.8× on Nov 11, 2026, against 19.5× a year earlier. Over the last 5 years it ranged from 2.4× to 172.7×, with a median of 19.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202673.8×+53.1
2025Dec 31, 202520.7×+14.2
2024Dec 31, 20246.5×+3.1
2023Dec 29, 20233.5×−41.2
2022Dec 30, 202244.7×−85.5
2021Dec 31, 2021130.2×+83.8
2020Dec 31, 202046.3×+34.8
2019Dec 31, 201911.5×−21.6
2018Dec 31, 201833.1×–

More Aclaris Therapeutics figures

See a number that looks wrong?